Effect of synbiotic supplementation on azotemia of patient with chronic kidney disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013062413756N1

Enrollment

Registered

2013-08-29

Start date

2013-08-24

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease. Chronic kidney disease

Interventions

Intervention 1: In the control group, Placebo capsules, 500 mg twice daily for 6 weeks. Intervention 2: In the intervention group, oral symbiotic capsules (FamiLact) 500 mg twice daily for 6 weeks.

Placebo

Treatment - Drugs

In the control group, Placebo capsules, 500 mg twice daily for 6 weeks.

In the intervention group, oral symbiotic capsules (FamiLact) 500 mg twice daily for 6 weeks.

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria included: age 65-30 years; chronic kidney disease stage 3 or 4 (GFR = 15-59ml/min/1.73m2). Exclusion criteria included: pregnant women; Lactulose or antibiotic consumption within 14 days before study; active addiction to alcohol; hepatitis, HIV and HIV infection and criteria for sample loss include: Lactulose or antibiotics consumption during the study and starting hemodialysis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
BUN. Timepoint: before and at the end of intervention. Method of measurement: In term of milligrams per deciliter and through blood test.;Blood Creatinine. Timepoint: before and at the end of intervention. Method of measurement: in terms of milligrams per deciliter and through blood test.;Uric acid. Timepoint: before and at the end of intervention. Method of measurement: in terrms of milligrams per deciliter and through blood test.;Creatinine clearance. Timepoint: before and at the end of intervention. Method of measurement: in terms of Milli liter per minute per 1.73 square meters and through blood and urine tests.;GFR. Timepoint: before and at the end of intervention. Method of measurement: in terms of milli liter per minute.	—

Measure

Time frame

BUN. Timepoint: before and at the end of intervention. Method of measurement: In term of milligrams per deciliter and through blood test.;Blood Creatinine. Timepoint: before and at the end of intervention. Method of measurement: in terms of milligrams per deciliter and through blood test.;Uric acid. Timepoint: before and at the end of intervention. Method of measurement: in terrms of milligrams per deciliter and through blood test.;Creatinine clearance. Timepoint: before and at the end of intervention. Method of measurement: in terms of Milli liter per minute per 1.73 square meters and through blood and urine tests.;GFR. Timepoint: before and at the end of intervention. Method of measurement: in terms of milli liter per minute.

—

Secondary

Measure	Time frame
Lipid profile include TG,Cholesterol,LDL,HDL. Timepoint: before and at the end of intervention. Method of measurement: In terms of milligrams per deciliter and through blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHeidari Fatemeh

Nursing and Midwifery College of Yazd university of medical sciences

Heidari_f20@sums.ac.ir+98 35 1824 9706

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026